Page last updated: 2024-12-07

wy 50324

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

WY 50324: structure given in first source; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID130918
CHEMBL ID545793
CHEMBL ID1194252
CHEMBL ID2111138
SCHEMBL ID247559
MeSH IDM0216811

Synonyms (30)

Synonym
w5u6wqm26h ,
tricyclo(3.3.1.1(3,7))decane-1-carboxamide, n-(2-(4-(2-pyrimidinyl)-1-piperazinyl)ethyl)-
unii-w5u6wqm26h
127266-56-2
adatanserin [inn]
wy 50324
wy-50324
adatanserin
adamantane-1-carboxylic acid [2-(4-pyrimidin-2-yl-piperazin-1-yl)-ethyl]-amide; dihydrochloride
bdbm50083287
CHEMBL545793 ,
L001372
n-[2-(4-pyrimidin-2-ylpiperazin-1-yl)ethyl]adamantane-1-carboxamide
CHEMBL1194252
n-(2-(4-(2-pyrimidinyl)-1-piperazinyl)ethyl)tricyclo(3.3.1.1(sup (3.7))decane-1-carboxamide
n-(2-(4-(2-pyrimidinyl)-1-piperazinyl)ethyl)-1-adamantanecarboxamide
tricyclo(3.3.1.13,7)decane-1-carboxamide, n-(2-(4-(2-pyrimidinyl)-1-piperazinyl)ethyl)
SCHEMBL247559
smr004703314
MLS006011548
CHEMBL2111138
Z749259376
sr-01000945138
SR-01000945138-1
n-{2-[4-(pyrimidin-2-yl)piperazin-1-yl]ethyl}adamantane-1-carboxamide
Q4680877
DTXSID90869749
tricyclo[3.3.1.13,7]decane-1-carboxamide, n-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]-
EN300-1700020
AKOS040745482
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (40.00)18.2507
2000's3 (60.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.66 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]